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Summary
Background: Because	 most	 pancreatic	 intraductal	 papillary	 mucinous	 neoplasms	
(IPMNs)	will	never	become	malignant,	currently	advocated	long‐term	surveillance	is	
low‐yield	for	most	individuals.
Aim: To	develop	a	score	chart	identifying	IPMNs	at	lowest	risk	of	developing	worri‐
some	features	or	high‐risk	stigmata.
Methods: We	combined	prospectively	maintained	pancreatic	cyst	surveillance	data‐
bases	of	three	academic	institutions.	Patients	were	included	if	they	had	a	presumed	
side‐branch	IPMN,	without	worrisome	features	or	high‐risk	stigmata	at	baseline	(as	de‐
fined	by	the	2012	international	Fukuoka	guidelines),	and	were	followed	≥	12	months.	
The	endpoint	was	development	of	one	or	more	worrisome	features	or	high‐risk	stig‐
mata	during	follow‐up.	We	created	a	multivariable	prediction	model	using	Cox‐pro‐
portional	logistic	regression	analysis	and	performed	an	internal‐external	validation.
Results: 875	patients	were	included.	After	a	mean	follow‐up	of	50	months	(range	12‐157),	
116	(13%)	patients	developed	worrisome	features	or	high‐risk	stigmata.	The	final	model	
included	 cyst	 size	 (HR	 1.12,	 95%	 CI	 1.09‐1.15),	 cyst	 multifocality	 (HR	 1.49,	 95%	 CI	
1.01‐2.18),	ever	having	smoked	(HR	1.40,	95%	CI	0.95‐2.04),	history	of	acute	pancreatitis	
(HR	2.07,	95%	CI	1.21‐3.55),	and	history	of	extrapancreatic	malignancy	(HR	1.34,	95%	CI	
0.91‐1.97).	After	validation,	the	model	had	good	discriminative	ability	(C‐statistic	0.72	in	
the	Mayo	cohort,	0.71	in	the	Columbia	cohort,	0.64	in	the	Erasmus	cohort).
Conclusion: In	presumed	side	branch	IPMNs	without	worrisome	features	or	high‐risk	
stigmata	at	baseline,	the	Dutch‐American	Risk	stratification	Tool	(DART‐1)	success‐
fully	 identifies	 pancreatic	 lesions	 at	 low	 risk	 of	 developing	worrisome	 features	 or	
high‐risk	stigmata.
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1  | INTRODUC TION
Pancreatic	 cystic	 lesions	 are	 a	 common,	 often	 incidental	 finding.	
Recent	large	studies	using	magnetic	resonance	cholangiopancrea‐
tography	 revealed	 a	 remarkably	 high	 prevalence	 in	 the	 general	
population,1,2	of	up	to	49%	and	even	up	to	60%	for	persons	over	
70	years.2	Many	of	these	lesions	are	neoplastic	mucinous	cysts,	a	
subgroup	with	a	varying	risk	of	malignant	progression,	depending	
on	pathological	subtype	and	extent	of	pancreatic	duct	involvement.
Of	all	neoplastic	cysts,	side	branch	intraductal	papillary	muci‐
nous	neoplasms	(SB‐IPMN)	are	the	most	common	and	deemed	to	
bear	the	lowest	risk	of	harbouring	malignancy	or	progressing	to	ma‐
lignancy.	Risk	estimations	were	initially	based	on	small,	retrospec‐
tive	series,	evaluating	mainly	resected	SB‐IPMN	in	tertiary	referral	
centres.3‐6	They	reported	a	risk	of	invasive	carcinoma	ranging	from	
11%6	 to	 29%.3	 However,	 several	 recent	 studies	 indicate	 a	 much	
lower	risk	for	incidentally	found	SB‐IPMN.	In	2015,	a	meta‐analysis	
was	published	 including	2177	patients	under	surveillance	 for	SB‐
IPMN,	of	which	only	82	(3.7%)	developed	a	pancreatic	malignancy.7 
Since	then,	several	additional	studies,	each	including	at	 least	300	
patients	with	at	 least	5	years	of	 follow‐up,	 reported	a	pancreatic	
cancer	 risk	 of	 only	 0%‐1.6%	 for	 small	 asymptomatic	 cysts.2,8‐12 
However,	all	these	studies	were	retrospective	and	the	actual,	long‐
term	risk	is	yet	to	be	determined	by	large	and	prospective	studies.
Pending	 definite	 answers,	 the	 European,13	 AGA,14	 ACG,15 and 
international	 Fukuoka16	 guidelines	 recommend	 surveillance	 with	
magnetic	 resonance	 imaging/magnetic	 resonance	 cholangiopan‐
creatography	and/or	endoscopic	ultrasound	for	all	IPMNs,	including	
small	unsuspected	cysts,	in	an	attempt	to	detect	pancreatic	cancer	in	
an	early	or	even	premalignant	stage.	These	recommendations	pose	a	
considerable	burden	on	patients	and	health	care	resources,	whereas	
the	clinical	benefit	with	regard	to	survival	remains	to	be	proven.
There	are	 currently	no	 tools	 to	distinguish	 IPMNs	 that	do	not	
warrant	surveillance,	or	that	are	helpful	 in	selecting	a	tailored	and	
optimal	 surveillance	 interval.	Previous	prediction	models	have	 fo‐
cused	on	 identifying	high‐risk	 IPMNs	to	 improve	patient	selection	
for	surgery.17‐24	Although	these	models	are	valuable	and	necessary,	
the	vast	majority	of	SB‐IPMNs	do	not	progress.	Therefore,	we	aimed	
to	develop	a	prediction	model	that	identifies	patients	with	SB‐IPMN	
at	 lowest	 risk	 of	 developing	worrisome	 features	 or	 high‐risk	 stig‐
mata.	Such	a	stratifying	tool	is	needed	to	prevent	redundant	surveil‐
lance	and	reduce	the	burden	for	patients	and	health	care	systems.
2  | MATERIAL S AND METHODS
2.1 | Study design
We	 included	 pancreatic	 cyst	 surveillance	 data	 from	 prospectively	
maintained	 databases	 of	 three	 academic	 institutions,	 namely	 the	
Erasmus	 University	 Medical	 Center,	 Rotterdam,	 the	 Netherlands;	
Columbia	University	Medical	Center,	New	York,	USA;	and	the	Mayo	
Clinic	Florida,	Jacksonville,	USA.	At	the	Erasmus	UMC,	the	study	was	
exempt	from	institutional	review	board	review	(MEC‐2018‐1285).	The	
study	received	IRB	approval	at	Columbia	UMC	(AAAO8260(M01Y04))	
and	at	the	Mayo	Clinic	(14‐007100).	The	need	for	written	informed	
consent	was	waived	by	the	Erasmus	UMC	and	Columbia	UMC.	At	the	
Mayo	Clinic	Florida,	verbal	informed	consent	was	obtained	from	each	
participant	 before	 enrolment.	 The	 study	 was	 performed	 according	
to	the	declaration	of	Helsinki	and	the	manuscript	complies	with	the	
statement	for	the	transparent	reporting	of	a	multivariable	prediction	
model	for	individual	prognosis	or	diagnosis	(TRIPOD).25
2.2 | Participants
The	databases	contain	all	consecutive	patients	under	surveillance	for	
a	pancreatic	cyst	since	2004	(Erasmus	University	Medical	Center),	
2003	(Columbia	University	Medical	Center),	and	2000	(Mayo	Clinic	
Florida).	 From	 these	 databases,	 we	 selected	 patients	 with	 a	 ra‐
diologically	 presumed	 SB‐IPMN	who	 had	 been	 followed‐up	 for	 at	
least	 12	months.	 A	 subset	 of	 these	 patients	 have	 been	 described	
previously.26	We	excluded	individuals	with	one	or	more	worrisome	
features	or	high‐risk	stigmata	at	baseline,	as	defined	in	the	2012	in‐
ternational	Fukuoka	guidelines27	(Figure	1).
2.3 | Endpoint and candidate predictors
The	 endpoint	 was	 defined	 as	 the	 development	 of	 one	 or	 more	
worrisome	 features	 or	 high‐risk	 stigmata	 according	 to	 the	 2012	
International	Fukuoka	guidelines.	Candidate	predictors	were	chosen	
based	on	prior	publications	and	medical	reasoning.	 Included	in	the	
analysis	were	age,	personal	history	of	diabetes	mellitus	(defined	as	
having	a	previous	diagnosis	in	electronic	medical	records),	body	mass	
index,	 ever	 having	 smoked	 personal	 history	 of	 acute	 pancreatitis,	
personal	history	of	any	type	of	extrapancreatic	malignancy,	 family	
history	 of	 pancreatic	 ductal	 adenocarcinoma,	 multifocality	 of	 the	
cyst,	and	the	diameter	of	the	largest	cyst.	All	variables	were	assessed	
at	the	time	of	cyst	diagnosis.
2.4 | Statistical analysis
Missing	 data	 were	 imputed	 using	 multiple	 imputation	 by	 chained	
equations	 (MICE)	 based	 on	 the	 posterior	 distributions	 with	 five	
datasets	with	 the	MICE	package	 in	 r	 software.28	We	used	 a	Cox‐
proportional	 logistic	 regression	analysis	 to	develop	a	multivariable	
prediction	model.	A	 linear	 relation	was	 the	 best	 approximation	of	
the	relationship	between	the	endpoint	and	the	continuous	predic‐
tors.	A	backward	stepwise	selection	procedure	was	performed	with	
Akaike's	 Information	Criterion	as	stopping	 rule,	 to	 limit	overfitting	
and	 to	prevent	exclusion	of	 important	predictors.	The	 final	model	
with	 the	 best	 predictive	 ability	was	 presented	with	 hazard	 ratios,	
and	95%	CIs	calculated	using	a	parametric	approach,	to	indicate	the	
individual	predictor	effects.	The	Cox‐proportional	hazard	assump‐
tion	was	checked	and	showed	nonsignificant	results,	indicating	that	
proportional	hazards	can	be	assumed.
We	first	performed	an	internal	validation	with	bootstrap	resa‐
mpling	with	500	replications	to	shrink	the	model's	coefficients	to	
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minimise	overfitting.29	Subsequently,	we	performed	an	internal‐ex‐
ternal	validation	of	the	final	model,	in	which	each	subcohort	was	in	
turn	omitted	from	the	development	set	and	subsequently	used	as	
validation	set	(Figure	1).	Model	performance	in	terms	of	discrimina‐
tive	ability	was	described	with	 the	Harrell's	 concordance	statistic	
(C‐statistic),	 which	 varies	 between	 0.5	 (a	 non‐informative	model)	
and	1.0	(a	perfect	model).	The	coefficients	were	used	to	calculate	
the	probability	of	developing	worrisome	features	or	high‐risk	stig‐
mata	within	three	years	and	within	5	years,	which	is	presented	in	a	
score	chart.	We	used	spss	Statistics	22	(IBM	Corporation,	Armonk,	
New	York,	USA)	and	R	Software	version	3.3.5	(R	foundation	for	sta‐
tistical	computing,	Vienna,	Austria)	for	the	statistical	analysis.
3  | RESULTS
3.1 | Participants and clinical outcome
We	 included	875	patients.	The	mean	age	was	66	 (SD	11.2)	 years,	
37%	(321)	were	male,	74%	(648)	Caucasian,	and	the	mean	body	mass	
index	was	27	(SD	4.9).	At	baseline,	multifocal	cysts	were	observed	in	
335	(38%)	patients	and	the	average	diameter	of	the	largest	cyst	was	
12	mm	(SD	6.4,	see	Table	1	for	all	baseline	characteristics).	After	a	
mean	follow‐up	of	50	months	(SD	28.5,	range	12‐157)	and	a	total	fol‐
low‐up	of	3649	person‐years,	116	(13.2%)	patients	developed	one	
or	more	worrisome	features	or	high‐risk	stigmata.	Table	2	shows	the	
baseline	characteristics	according	to	outcome.
In	the	group	who	developed	a	worrisome	feature,	surgery	was	per‐
formed	on	36	(31%)	patients.	Pathology	showed	an	invasive	carcinoma	
in	three	patients,	high‐grade	dysplasia	in	six	patients,	low	or	moderate	
grade	dysplasia	in	22	patients,	a	neuroendocrine	tumour	in	one	patient,	
and	a	mucinous	cystic	neoplasm	in	four	patients.	In	the	group	without	
a	worrisome	feature	during	follow‐up,	surgery	was	performed	on	20	
(2.6%)	patients.	Reasons	for	this	included	the	presence	of	symptoms	
(other	than	 jaundice	or	current	pancreatitis),	minor	growth	of	a	cyst	
smaller	than	3	cm,	an	increased	cyst	fluid	carcinoembryonic	antigen	
level,	a	pancreatitis	episode	in	the	past	(but	not	at	the	moment	of	cyst	
detection),	the	patient's	wishes,	or	a	combination	of	these	reasons.	In	
these	cases,	pathology	showed	only	low	or	moderate	grade	dysplasia	
(18)	or	a	mucinous	cystic	neoplasm	(2).	Of	the	non‐operated	patients,	
none	were	diagnosed	with	pancreatic	cancer	during	follow‐up.
3.2 | Missing data and model specification
None	of	the	patients	had	missing	data	for	the	endpoint,	age,	cyst	
multifocality,	or	initial	cyst	size.	There	was	≤	5%	missing	data	for	
smoking	behaviour	(4.5%),	personal	history	of	diabetes	(0.6%),	per‐
sonal	history	of	acute	pancreatitis	 (2.1%),	personal	history	of	ex‐
trapancreatic	malignancy	(1.0%),	and	family	history	of	pancreatic	
F I G U R E  1  Flow‐chart	of	patient	
selection	and	model	development	process All patients under surveillance for presumed IPMN
Exclusion of patients with at baseline having any of:
1. Jaundice
2. Enhancing solid component
3. Main PD ≥ 10mm
Exclusion of patients with <12 months follow-up
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Index = 14
Development set
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ductal	 adenocarcinoma	 (4.3%).	 For	 body	 mass	 index,	 data	 were	
missing	for	200	(23%)	patients.
The	model	with	the	best	fit	included	cyst	size	(HR	1.12,	95%	CI	
1.09‐1.15),	cyst	multifocality	(HR	1.49,	95%	CI	1.01‐2.18),	ever	having	
smoked	 (HR	1.40,	 95%	CI	 0.95‐2.04),	 history	 of	 acute	 pancreatitis	
(HR	2.07,	95%	CI	1.21‐3.55),	 and	history	of	 extrapancreatic	malig‐
nancy	(HR	1.34,	95%	CI	0.91‐1.97).	The	hazard	ratios	and	95%	CI	of	
each predictive variable in both univariable and multivariable analy‐
sis	are	shown	in	Table	3.
3.3 | Model performance
Bootstrap	resampling	showed	limited	optimism	in	the	C‐statistic	of	
0.02.	In	the	internal‐external	validation,	model	performance	varied	
between	 the	 three	 subcohorts.	 The	 model	 showed	 the	 best	 dis‐
criminative	ability	in	the	cohorts	of	Mayo	Clinic	Florida	(C‐statistic	
0.72,	95%	CI	0.61‐0.84)	and	Columbia	UMC	(C‐statistic	0.71,	95%	CI	
0.66‐0.80).	The	performance	within	the	Erasmus	UMC	cohort	was	
0.64	(95%	CI	0.57‐0.88).
3.4 | Score chart and example
The	Dutch‐American	 Risk	 stratification	 Tool	 (DART‐1)	 visualises	 the	
estimated	3‐year	and	5‐year	risk	of	developing	one	or	more	worrisome	
features	or	high‐risk	stigmata	for	all	possible	predictor	combinations	
(Figure	 2A,B).	 A	 web‐based	 application	 has	 been	 developed	 and	 is	
available	at	https	://rtools.mayo.edu/DART/	(Figure	3).	When	using	the	
DART‐1,	a	patient	with	a	unifocal	cyst	smaller	than	1	cm,	without	a	his‐
tory	of	acute	pancreatitis,	extrapancreatic	malignancy	or	smoking,	has	
an	estimated	3‐year	risk	of	≤	2%	and	5‐year	risk	of	≤	5%	to	develop	one	
or	more	worrisome	features	or	high‐risk	stigmata.
4  | DISCUSSION
In	this	international	multicentre	study,	we	describe	the	development	
of	 DART‐1,	 the	 first	 version	 of	 a	 prediction	 model	 that	 does	 not	
focus	on	identifying	IPMNs	at	high	risk	of	malignancy,	but	on	those	
at	low	risk	instead.	It	is	based	on	patient	and	cyst	characteristics	that	
 
Erasmus UMC 
(n = 79)
Columbia UMC 
(n = 483)
Mayo Clinic 
Florida (n = 313)
Patient	characteristics
Age,	mean	(SD),	y 61	(11.0) 65	(11.9) 68	(9.5)
Male	gender 20	(25.3) 197	(40.8) 104	(33.2)
Race
Caucasian 64	(81.0) 295	(61.1) 289	(92.3)
Asian 2	(2.5) 20	(4.1) 3	(1.0)
Black 4	(5.1) 30	(6.2) 16	(5.1)
Other 4	(5.1) 16	(3.3) 1	(0.3)
Unknown 5	(6.3) 122	(25.3) 4	(1.3)
Diabetes	mellitus 10	(12.7) 119	(24.6) 46	(14.7)
Body	mass	index,	mean	
(SD)
27	(5.6) 27	(5.0) 27	(4.8)
Smoking	ever 27	(34.2) 189	(39.1) 126	(40.3)
Alcohol ever 38	(48.1) 198	(41) 136	(43.5)
History	of	acute	
pancreatitis
9	(11.3) 48	(9.9) 13	(4.2)
History	of	extrapancreatic	
malignancy
12	(15.2) 195	(40.4) 84	(26.8)
Family	history	of	PDAC 10	(12.7) 50	(10.4) 30	(9.6)
Cyst	characteristics
Location	dominant	cyst
Head 52	(65.8) 188	(38.9) 141	(45.0)
Body 22	(27.8) 188	(38.9) 103	(32.9)
Tail 4	(5.1) 106	(21.9) 68	(21.7)
Multifocality 43	(54.4) 188	(38.9) 104	(33.2)
Largest	diameter,	mean	
(SD),	mm
13	(6.6) 11.5	(6.5) 12	(6.1)
Note: Values	presented	as	n	(%)	unless	otherwise	indicated.
Abbreviations:	PDAC,	pancreatic	ductal	adenocarcinoma;	SD,	standard	deviation.
TA B L E  1  Baseline	patient	and	cyst	
characteristics
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can	 be	 assessed	 at	 the	 time	 of	 diagnosis,	 and	 predicts	 the	 3‐year	
and	5‐year	risk	of	developing	worrisome	features	or	high‐risk	stig‐
mata	as	defined	by	the	2012	international	Fukuoka	guidelines.	Such	
a	model	is	important,	as	pancreatic	cysts	are	diagnosed	with	increas‐
ing	 frequency	and	yearly	 imaging	 is	generally	 recommended,	even	
though	the	majority	of	lesions	are	at	low	risk	of	malignant	progres‐
sion.	Using	a	stratifying	tool,	clinicians	can	make	evidence‐based	risk	
estimations	for	progression	in	individual	patients	and	identify	those	
at	lowest	risk.	The	ultimate	goal	would	be	to	decrease	the	burden	of	
surveillance	on	patients,	but	also	on	health	care	resources	by	either	
optimising	 surveillance	 intervals	 or,	 in	 selected	 cases,	 discontinue	
surveillance.
In	our	 cohort,	multivariable	 analysis	 resulted	 in	 five	predictors	
for	 progression:	 cyst	 size,	 cyst	 multifocality,	 ever	 having	 smoked	
history	 of	 acute	 pancreatitis,	 and	 history	 of	 extrapancreatic	 ma‐
lignancy.	 Cyst	 size	 being	 an	 independent	 predictor	 of	 progression	
comes	as	no	surprise,	given	that	a	size	of	3	centimetres	or	greater	is	
defined	as	a	worrisome	feature27 and therefore incorporated in our 
composite	endpoint.	However,	 it	has	been	shown	in	other	cohorts	
that	initial	cyst	size	is	a	predictor	of	cyst	growth,30‐32 development 
 Total (N = 875)
No development of WF 
or HRS (n = 759)
Development of WF or 
HRS (n = 116)
Centre
Erasmus	UMC 79	(9.0) 65	(8.6) 14	(12.1)
Columbia	UMC 483	(55.2) 410	(54.0) 73	(62.9)
Mayo	
Clinic	Florida
313	(35.8) 284	(37.4) 29	(25.0)
Patient	characteristics
Age,	mean	(SD),	y 66	(11.2) 65	(10.9) 67	(12.8)
Male	gender 321	(36.7) 271	(35.7) 50	(43.1)
Race
Caucasian 648	(74.1) 568	(74.8) 80	(69.0)
Asian 25	(2.9) 22	(2.9) 3	(2.6)
Black 50	(5.7) 41	(5.4) 9	(7.8)
Other 21	(2.3) 18	(2.4) 3	(2.6)
Unknown 131	(15.0) 110	(14.5) 21	(18.1)
Diabetes	mellitus 175	(20.0) 148	(19.5) 27	(23.3)
Body	mass	index,	
mean	(SD)
27	(4.9) 27	(4.9) 27	(5.3)
Smoking	ever 342	(39.1) 288	(37.9) 54	(46.6)
Alcohol ever 372	(42.5) 319	(42.0) 53	(45.7)
History	of	acute	
pancreatitis
70	(8.0) 54	(7.1) 16	(13.8)
History	of	
extrapancreatic	
malignancy
291	(33.3) 246	(32.4) 45	(38.8)
Family	history	of	
PDAC
90	(10.3) 80	(10.5) 10	(8.6)
Cyst	characteristics
Location	dominant	cyst
Head 381	(43.5) 329	(43.3) 52	(44.8)
Body 313	(35.8) 274	(36.1) 39	(33.6)
Tail 178	(20.3) 153	(20.2) 25	(21.6)
Multifocality 335	(38.3) 280	(36.9) 55	(47.4)
Largest	diameter,	
mean	(SD),	mm
12	(6.4) 11	(6.0) 17	(6.7)
Note: Values	presented	as	n	(%)	unless	otherwise	indicated.
Abbreviations:	HRS,	high‐risk	stigmata;	PDAC,	pancreatic	ductal	adenocarcinoma;	SD,	standard	
deviation;	WF,	worrisome	feature.
TA B L E  2  Patient	and	cyst	
characteristics	separated	on	study	
endpoint
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of	other	worrisome	features,31,33 and malignancy.12 The predictive 
value	of	cyst	multifocality	has	been	described	less	often,	but	is	not	
a	new	finding.	Crippa	et	al	followed	144	patients	with	SB‐IPMN	for	
5	 years,	 and	 found	 that	 an	 increase	 in	 the	 number	 of	 lesions	was	
associated	with	the	development	of	worrisome	features	or	high‐risk	
stigmata	(OR	6,	95%	CI	1.7‐20.8).33	It	was	also	identified	as	predictor	
in	an	earlier	analysis	of	a	subset	of	our	cohort.26	A	history	of	smoking	
and	of	acute	pancreatitis	are	well‐established	risk	factors	for	pancre‐
atic	cancer,34‐37	but	not	for	the	development	of	worrisome	features	
in	IPMN.	Some	studies	suggest	smoking	accelerates	progression	of	
IPMN,	and	that	it	predicts	invasive	IPMN	or	concomitant	pancreatic	
cancer	in	resected	IPMN,	but	results	are	conflicting.38‐41
A	history	of	extrapancreatic	malignancy	has	not	been	described	
as	 a	 predictor	 for	 progression	 in	 other	 cohorts.	 In	 the	 previous	
analysis	 of	 a	 subset	 of	 our	 cohort,	 a	 history	 of	 any	 extrapancre‐
atic	malignancy	was	not	an	independent	predictor,	but	a	history	of	
prostate	 cancer	was.	 This	 difference	 is	most	 likely	 attributable	 to	
the	difference	 in	sample	size.	Retrospective	studies	have	reported	
an	 increased	 incidence	of	extrapancreatic	malignancies	 in	patients	
with	IPMN,	but	prospective	studies	were	unable	to	confirm	this.8,42 
Crippa	et	al	did	not	find	an	association	between	extrapancreatic	tu‐
mors	 and	 the	 development	 of	 worrisome	 features,33	 but	 because	
their	cohort	consisted	of	144	patients	of	which	only	26	developed	
worrisome	features	or	high‐risk	stigmata,	this	may	be	due	to	a	lack	
of	power.	The	predictive	value	of	a	history	of	an	extrapancreatic	ma‐
lignancy	on	progression	of	IPMN	has	to	be	confirmed	by	studies	in	
other	cohorts.
Having	 a	 history	 of	 diabetes	was	 predictive	 in	 the	 univariable	
analysis	 but	 did	 not	 contribute	 significantly	 to	 the	 multivariable	
model	 and	 was	 therefore	 omitted	 from	 DART‐1.	 The	 association	
between	 diabetes	 and	 pancreatic	 cancer	 is	 well‐known,43‐46 but 
the	 association	with	 IPMN	 is	 less	 established.	 Some	 studies	 have	
reported	 an	 increased	 risk	 for	 patients	 with	 diabetes	 to	 develop	
IPMN,1,47	but	 in	another	 large	population‐based	study,	 this	associ‐
ation	 disappeared	 after	 correcting	 for	 age	 and	 body	mass	 index.2 
Morales‐Oyarvide	et	al	showed	that	in	patients	with	resected	IPMN,	
preoperative	 diabetes	 is	 associated	with	 high‐grade	 dysplasia	 and	
invasive	carcinoma,48	suggesting	diabetes	has	a	proliferative	effect	
on	the	cyst.	However,	to	the	best	of	our	knowledge,	there	have	been	
no	studies	that	demonstrate	that	diabetes	is	associated	with	the	de‐
velopment	of	worrisome	features	and	high‐risk	stigmata.	Although	
diabetes	did	not	contribute	to	the	predictive	ability	of	the	model	in	
our	cohort,	it	should	be	included	in	validation	studies	and	future	up‐
dates	of	DART‐1,	to	further	establish	its	value.
We	 encountered	 some	minor	 differences	 between	 the	 subco‐
horts,	the	most	noticeable	being	a	higher	prevalence	of	diabetes	and	
personal	history	of	extrapancreatic	malignancy	in	the	Columbia	co‐
hort,	and	more	multifocal	cysts	in	the	Erasmus	cohort.	However,	any	
meaningful	differences	between	the	subcohorts	were	ruled	out	by	
the	internal‐external	validation.	In	this	type	of	validation,	each	sub‐
cohort	is	in	turn	left	out	from	the	development	set	and	used	as	a	val‐
idation	set.	The	final	model	is	then	based	on	all	available	data.	Such	
an	internal‐external	cross‐validation	can	be	used	to	demonstrate	ex‐
ternal	validity	of	a	prediction	model,	with	the	additional	advantage	
that	 sample	 size	 is	 retained.49	 DART‐1	 performed	 similarly	 in	 the	
total	cohort	before	validation	(apparent	performance),	the	Columbia	
cohort,	 and	 the	Mayo	 cohort.	 The	 slight	decrease	 in	performance	
within	the	Erasmus	cohort	was	expected	and	is	attributable	to	this	
cohort's	smaller	sample	size.
DART‐1	 shows	 promise,	 but	 should	 be	 interpreted	 with	 some	
caution.	 Foremost,	 prediction	 models	 are	 developed	 to	 augment,	
and	not	replace	clinical	judgment,	and	the	given	risks	are	estimates	
that	 therefore	 hold	 some	 extent	 of	 uncertainty.	 Also,	 it	 is	 crucial	
that	DART‐1	is	validated	in	other	cohorts	before	 it	 is	 implemented	
in	clinical	care.	We	expect	DART‐1	will	be	highly	generalisable	be‐
cause	our	development	set	encompasses	three	centres,	each	located	
in	a	different	geographical	region,	and	each	collecting	patient	data	in	
slightly	different	time	periods.	Also,	our	cohort	consists	of	patients	
without	complex	cysts,	and	is	therefore	likely	to	be	comparable	to	
the	 patient	 population	 in	 the	 primary	 or	 secondary	 care	 setting.	
Additionally,	 we	 observed	 limited	 optimism	 in	 the	 C‐statistic	 and,	
therefore,	a	good	external	performance	is	likely.
The	main	limitation	of	this	prediction	model	is	that	it	uses	a	com‐
posite,	 surrogate	 endpoint.	 Ideally	 it	 would	 predict	 development	
of	malignancy.	However,	given	the	low	cancer	risk	of	SB‐IPMNs,	 it	
would	require	extremely	large	cohorts	to	reach	adequate	numbers	
for	 statistical	modeling.	 Although	we	 collected	 one	 of	 the	 largest	
low‐risk	SB‐IPMN	cohorts,	 it	did	not	yield	enough	pancreatic	can‐
cer	cases	for	 this	purpose,	and	we	are	unable	to	make	predictions	
on	the	development	of	malignancy.	However,	the	ultimate	objective	
of	DART‐1	is	not	to	 identify	high‐risk	IPMNs,	but	those	unlikely	to	
develop	 into	malignancy.	 Although	 it	 has	 been	 shown	 that	worri‐
some	 features	and	high‐risk	stigmata	accurately	 stratify	 for	malig‐
nancy	 risk,50	 it	 is	 also	 known	 that	 a	 substantial	 number	of	 IPMNs	
with	a	worrisome	feature	do	not	harbor	high‐grade	dysplasia	or	in‐
vasive	carcinoma,21‐23	which	is	supported	by	our	own	results.	IPMNs	
TA B L E  3  Candidate	predictors	with	associated	hazard	ratios
Predictor
Univariable
Final multivariable 
model
HR 95% CI HR 95% CI
Age 1.01 0.99‐1.03 NA NA
Body	mass	index 1.01 0.96‐1.05 NA NA
Smoking,	ever 1.42 0.98‐2.05 1.40 0.95‐2.04
History	of	diabetes	
mellitus
1.37 0.89‐2.12 NA NA
History	of	acute	
pancreatitis
1.76 1.04‐2.99 2.07 1.21‐3.55
History	of	extrapan‐
creatic malignancy
1.21 0.83‐1.76 1.34 0.91‐1.97
Cyst	multifocality 1.65 1.14‐2.41 1.49 1.01‐2.18
Largest	cyst	diameter,	
per mm
1.12 1.09‐1.15 1.12 1.09‐1.15
Abbreviations:	CI,	confidence	interval;	HR,	hazard	ratio;	NA,	not	ap‐
plicable,	was	not	included	in	the	model	with	the	best	fit.
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without	worrisome	features	harbour	an	even	lower	risk	of	develop‐
ing	pancreatic	cancer,	which	strengthens	the	usefulness	of	DART‐1	
as	a	negative	prediction	tool	that	can	be	used	to	identify	those	SB‐
IPMNs	that	require	less	intense	surveillance.
A	second	limitation	is	that	we	have	based	our	endpoint	on	the	
2012	 international	 Fukuoka	 guidelines,27	 whereas	 these	were	 re‐
vised	 in	2017.16	Similar	 to	 the	European	guidelines,13 the updated 
version	includes	elevated	serum	carbohydrate	antigen	19‐9	levels	as	
a	worrisome	feature,	as	well	as	cyst	growth.	In	our	cohorts,	serum	
carbohydrate	antigen	19‐9	 levels	and	exact	 cyst	growth	were	not	
routinely	determined	and	recorded	in	the	past,	because	they	were	
under	surveillance	 long	before	guidelines	stressed	the	 importance	
of	 these	 parameters.	 Because	 previous	 studies	 have	 shown	 that	
cysts	not	necessarily	display	 a	 linear	 growth	pattern31,32 and that 
there	is	a	variability	in	size	measurement	between	imaging	modal‐
ities51	and	between	observers,52	 it	was	not	possible	to	reliably	as‐
sess	growth	rate	 retrospectively.	Therefore,	we	could	not	use	 the	
updated	 guidelines,	 and	 fast‐growing	 IPMNs	 that	 did	 not	 reach	
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F I G U R E  2  The	Dutch‐American	Risk	stratification	Tool	(DART‐1)	to	identify	side	branch	intraductal	papillary	mucinous	neoplasms	(SB‐
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3	cm	during	the	follow‐up	period,	may	have	been	misidentified	as	
non‐progressors.	Now	that	serum	carbohydrate	antigen	19‐9	levels	
and	growth	rates	are	routinely	determined	as	per	guidelines,	it	will	
be	possible	to	include	these	variables	as	part	of	the	study	endpoint	
or	 as	 predictor	 in	 future	 updates.	 Another	 aspect	 that	 could	 not	
be	completely	ruled	out,	 is	 if	our	dataset	contained	a	bias	by	right	
censoring.	However,	 the	predictors	 in	 the	model	did	not	 show	an	
association	with	 follow‐up	 time,	 limiting	 the	 possible	 influence	 of	
this	type	of	bias.
An	 issue	 of	much	 debate	 is	whether	 the	 risk	 of	malignancy	 in‐
creases	over	time.	Some	recent	studies	have	shown	that	even	small	
SB‐IPMN	may	evolve	into	malignancy	after	5	or	10	years,11,12,33 and 
that	a	stable	cyst	size	for	5	years	does	not	preclude	future	growth.53 
Because	our	study	population	has	a	mean	follow‐up	of	50	months,	we	
are	not	yet	able	to	determine	these	 long‐term	risks.	At	this	point	 in	
time,	this	precludes	us	from	stopping	surveillance	altogether,	based	
on	DART‐1.	Therefore,	we	do	not	advocate	a	complete	stop	of	sur‐
veillance,	but	 suggest	a	 reduction	of	 surveillance	 frequency	 for	 the	
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lowest	risk	SB‐IPMNs,	the	ideal	cut‐off	for	which	requires	further	cal‐
culation	in	external	cohorts.	It	is	essential	to	update	DART‐1	based	on	
long‐term,	prospective	data.	Additional	predictors	should	be	explored,	
such	 as	 diabetes,	 glycated	 haemoglobin	 or	 serum	 fasting	 glucose,	
serum	carbohydrate	antigen	19‐9	level,	or	other	promising	biomark‐
ers.	It	may	also	be	of	interest	to	objectify	smoking	exposure,	that	is,	
using	pack	years	as	a	predictor	rather	than	a	history	of	smoking.	It	is	
also	conceivable	that	current	smokers	are	at	higher	risk	than	former	
smokers.	Cyst	growth	may	also	be	a	strong	predictor,	but	 including	
this	will	render	the	model	unfit	for	use	at	the	time	of	cyst	diagnosis.
In	conclusion,	we	have	developed	a	prediction	model	that	does	not	
focus	on	detecting	high‐risk	 IPMNs,	but	 identifies	 IPMNs	at	 lowest	
risk	of	developing	worrisome	features	or	high‐risk	stigmata	instead,	by	
combining	variables	readily	available	at	the	time	of	cyst	diagnosis.	Even	
though	DART‐1	is	the	first	version	of	this	type	of	prediction	model,	it	
had	a	good	performance	 in	an	 internal‐external	validation,	and	high	
generalisability	to	other	cohorts	 is	expected.	After	DART‐1	 is	exter‐
nally	validated	by	others,	it	can	be	used	to	explore	varying	surveillance	
strategies	using	looser	follow‐up	policies	for	IPMNs	at	lowest	risk.	This	
very	novel	approach	of	stratifying	IPMNs	has	the	potential	to	protect	
patients	with	low‐risk	IPMNs	from	redundant	medical	interventions,	
and	to	reduce	costs	and	the	burden	for	the	health	care	system.
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Dutch-American Risk Stratification Tool Calculation About DISCLAIMER
DART-I Score
The three year risk is 2.15 out of 100.
Cyst size (mm):
Is the patient a former or current smoker?
Is the cyst multifocal?
Does the patient have a history of acute pancreatitis?
Does the patient have a history of extrapancreatic
malignancy?
Yes
No
Yes
No
Yes
No
Yes
No
2 28
2 5 8 11 14 17 20 23 26 28
9
3-year Risk
2/100 atrisk 5/100 atrisk 95/100 notatrisk98/100 notatrisk
5-year Risk
5.02
0 100
2.15
0 100
The five year risk is 5.02 out of 100.
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